Format

Send to

Choose Destination
Trends Neurosci. 2016 Nov;39(11):750-762. doi: 10.1016/j.tins.2016.09.003. Epub 2016 Oct 21.

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

Author information

1
Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, ONT, Canada. Electronic address: naomi.visanji@uhnresearch.ca.
2
The Krembil Institute, University Health Network, Toronto, ONT, Canada.
3
Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, ONT, Canada; The Krembil Institute, University Health Network, Toronto, ONT, Canada; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ONT, Canada; Department of Medicine, University of Toronto, Toronto, ONT, Canada.
4
Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ONT, Canada; Department of Medicine, University of Toronto, Toronto, ONT, Canada.
5
Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ONT, Canada; Department of Biochemistry, University of Toronto, Toronto, ONT, Canada.

Abstract

In recent years, a new generation of animal models of Parkinson's disease (PD) based on ectopic expression, overexpression, or intracerebral injection of the protein α-synuclein have emerged. Critically, these models develop inclusions of aggregated α-synuclein and/or α-synuclein-mediated neuronal loss replicating the defining pathological hallmarks of PD and driving significant advances in the understanding of the pathogenic mechanisms underpinning PD. Here, we provide a comprehensive review of this new generation of animal models of PD, ranging from invertebrate to rodent to nonhuman primate. We focus on their strengths and limitations with respect to their highly anticipated contribution to the further understanding of α-synuclein pathobiology and the future testing of novel disease-modifying therapeutics.

KEYWORDS:

Parkinson's disease; alpha synuclein; animal models; drug development; prion; transgenic

PMID:
27776749
DOI:
10.1016/j.tins.2016.09.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center